|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
37,470,000 |
Market
Cap: |
308.38(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.28 - $13.99 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
4,872,988 |
Total Buy Value |
$0 |
$0 |
$0 |
$41,694,868 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
13,472 |
42,011 |
76,578 |
2,756,162 |
Total Sell Value |
$132,861 |
$344,745 |
$641,708 |
$21,052,273 |
Total People Sold |
2 |
4 |
4 |
9 |
Total Sell Transactions |
2 |
9 |
13 |
45 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Burek Julie |
VP, Finance |
|
2022-02-11 |
4 |
AS |
$3.36 |
$1,213 |
D/D |
(361) |
55,896 |
|
75% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2022-02-11 |
4 |
AS |
$3.36 |
$10,927 |
D/D |
(3,252) |
126,804 |
|
75% |
|
Swartz Robin |
Chief Operating OfficerOfficer |
|
2022-02-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
58,000 |
|
45% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
130,056 |
|
- |
|
Pierce Glenn |
Interim CSO |
|
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
26,300 |
26,300 |
|
- |
|
Higgins Michael J |
Interim President & CEO |
|
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
45,205 |
45,205 |
|
- |
|
Burek Julie |
VP, Finance |
|
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
56,257 |
|
- |
|
Burek Julie |
VP, Finance |
|
2022-01-12 |
4 |
AS |
$3.06 |
$811 |
D/D |
(265) |
46,257 |
|
113% |
|
Burek Julie |
VP, Finance |
|
2022-01-03 |
4 |
AS |
$2.83 |
$8,668 |
D/D |
(3,063) |
46,522 |
|
105% |
|
Burek Julie |
VP, Finance |
|
2021-12-31 |
4 |
A |
$2.30 |
$7,045 |
D/D |
3,063 |
49,585 |
|
- |
|
Burek Julie |
VP, Finance |
|
2021-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,500 |
46,522 |
|
- |
|
Khwaja Omar |
See remarks |
|
2021-05-21 |
4 |
AS |
$4.03 |
$14,169 |
D/D |
(3,516) |
120,509 |
|
-38% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2021-04-05 |
4 |
S |
$4.95 |
$16,295 |
D/D |
(3,292) |
110,056 |
|
41% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
113,348 |
|
- |
|
Dorval Allison |
Chief Financial Officer |
|
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
109,894 |
|
- |
|
Turenne Andre |
President & CEO |
|
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
322,375 |
|
- |
|
Khwaja Omar |
See Remarks |
|
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
124,025 |
|
- |
|
Khwaja Omar |
See Remarks |
|
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
36,000 |
89,025 |
|
- |
|
Dorval Allison |
Chief Financial Officer |
|
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
79,894 |
|
- |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
83,348 |
|
- |
|
Turenne Andre |
President & CEO |
|
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
94,000 |
242,375 |
|
- |
|
Khwaja Omar |
See remarks |
|
2021-02-11 |
4 |
AS |
$7.55 |
$26,236 |
D/D |
(3,475) |
53,025 |
|
-40% |
|
Turenne Andre |
President & CEO |
|
2021-02-11 |
4 |
AS |
$7.55 |
$60,226 |
D/D |
(7,977) |
148,375 |
|
-40% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2021-02-11 |
4 |
AS |
$7.55 |
$24,054 |
D/D |
(3,186) |
49,348 |
|
-40% |
|
Dorval Allison |
Chief Financial Officer |
|
2021-02-11 |
4 |
AS |
$7.55 |
$24,054 |
D/D |
(3,186) |
45,894 |
|
-40% |
|
162 Records found
|
|
Page 4 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|